IQWIG published preliminary report for telemonitoring with the use of implantable cardioverter defibrillators (ICD) in ventricular tachyarrhythmia and heart failure

In 2016, Joint Federal Committee (G-BA) commissioned Institute for Quality and Efficiency in Health Care (IQWIG) for benefit assessment of telemonitoring systems in patients with implantable cardioverter defibrillators (ICD). In July 2017, IQWIG published a preliminary report. Due to lack of evidence, no benefit statement was made. 

In accordance with preliminary results, data for telemonitoring is incomplete. Available evidence does not demonstrate advantages and disadvantages of the application of these technologies regarding safety and efficacy endpoints (mortality, stroke, cardiac decompensation, myocardial infarction, cardiac arrhythmia, thromboembolic events, health condition, heart failure-related morbidity, mental morbidity, cardiac transplant, hospitalization, and shocks). In addition to the 16 included studies, 3 likely relevant, completed studies were identified without reported results. Distortion due to these data gaps is possible. Therefore, no benefit statement was given for these endpoints. The conclusion with recommendations should be given when missing data are available.

Now preliminary results are in the process of discussion and comments can be submitted to IQWIG by stakeholders.

See full report in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.